BioXcel Files Chapter 11, Teva to Serve as Stalking Horse Bidder for Assets
BTAI is trading near its 52-week low of $0.7 (25% below the low).
Summary
BioXcel Therapeutics has entered into an asset sale agreement with Teva Pharmaceuticals, which will serve as the stalking horse bidder in a court-supervised 363 auction for substantially all of the company's assets, including IGALMI and the pending sNDA for BXCL501. The deal includes $57.5 million in cash and up to $67.5 million in development milestones. BioXcel also filed for Chapter 11 bankruptcy in Delaware and secured a $19 million DIP financing commitment from existing lenders. The PDUFA date for the sNDA is November 14, 2026, which could affect the value of the assets in the auction. The sale process is intended to maximize value for stakeholders, but the company's equity is likely to be wiped out in bankruptcy, and the stock is trading near its 52-week low.
At the time of this announcement, BTAI was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.5M. The 52-week trading range was $0.70 to $5.19. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.